Replimune Group (REPL) Competitors $13.94 -0.12 (-0.85%) Closing price 02/7/2025 04:00 PM EasternExtended Trading$13.97 +0.03 (+0.22%) As of 02/7/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends REPL vs. RYTM, CRNX, APLS, IMVT, VKTX, ACLX, DNLI, TWST, ACAD, and XENEShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Rhythm Pharmaceuticals (RYTM), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Viking Therapeutics (VKTX), Arcellx (ACLX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Rhythm Pharmaceuticals Crinetics Pharmaceuticals Apellis Pharmaceuticals Immunovant Viking Therapeutics Arcellx Denali Therapeutics Twist Bioscience ACADIA Pharmaceuticals Xenon Pharmaceuticals Rhythm Pharmaceuticals (NASDAQ:RYTM) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking. Which has more risk and volatility, RYTM or REPL? Rhythm Pharmaceuticals has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Is RYTM or REPL more profitable? Replimune Group has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Replimune Group's return on equity of -53.12% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Replimune Group N/A -53.12%-41.49% Which has preferable valuation & earnings, RYTM or REPL? Rhythm Pharmaceuticals has higher revenue and earnings than Replimune Group. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$77.43M46.97-$184.68M-$4.33-13.67Replimune GroupN/AN/A-$215.79M-$3.05-4.57 Do institutionals and insiders hold more shares of RYTM or REPL? 92.5% of Replimune Group shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate RYTM or REPL? Rhythm Pharmaceuticals presently has a consensus target price of $68.09, indicating a potential upside of 15.06%. Replimune Group has a consensus target price of $19.14, indicating a potential upside of 37.32%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in RYTM or REPL? Rhythm Pharmaceuticals received 129 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 67.12% of users gave Rhythm Pharmaceuticals an outperform vote while only 63.74% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes29667.12% Underperform Votes14532.88% Replimune GroupOutperform Votes16763.74% Underperform Votes9536.26% Does the media prefer RYTM or REPL? In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Replimune Group. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 2 mentions for Replimune Group. Rhythm Pharmaceuticals' average media sentiment score of 0.33 beat Replimune Group's score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryReplimune Group beats Rhythm Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$961.95M$3.09B$5.75B$9.10BDividend YieldN/A1.79%5.30%4.00%P/E Ratio-4.5746.3089.2219.39Price / SalesN/A439.721,022.5981.33Price / CashN/A192.7646.1438.79Price / Book2.294.075.134.75Net Income-$215.79M-$41.02M$114.53M$222.93M7 Day Performance-0.29%0.41%-0.47%0.14%1 Month Performance20.90%-3.10%0.11%-0.13%1 Year Performance80.57%-2.37%23.87%21.23% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group3.9556 of 5 stars$13.94-0.9%$19.14+37.3%+87.9%$961.95MN/A-4.57210Upcoming EarningsRYTMRhythm Pharmaceuticals3.6885 of 5 stars$59.410.0%$68.09+14.6%+23.8%$3.65B$77.43M-13.72140Insider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals4.3304 of 5 stars$38.84-3.6%$72.64+87.0%-2.1%$3.60B$1.04M-10.41210Analyst ForecastInsider TradeAnalyst RevisionNews CoverageAPLSApellis Pharmaceuticals4.388 of 5 stars$28.53-1.7%$46.71+63.7%-55.9%$3.55B$715.22M-14.05770Gap DownIMVTImmunovant2.8479 of 5 stars$20.84-4.1%$47.00+125.5%-42.1%$3.54BN/A-9.39120Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageVKTXViking Therapeutics4.4705 of 5 stars$31.48-3.9%$106.75+239.2%+33.0%$3.51BN/A-33.8420Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageACLXArcellx2.7672 of 5 stars$64.73-5.0%$105.93+63.7%+4.8%$3.50B$110.32M-91.1680DNLIDenali Therapeutics4.2867 of 5 stars$21.88-6.1%$38.00+73.7%+31.3%$3.15B$330.53M-7.93430TWSTTwist Bioscience2.9318 of 5 stars$52.72+0.7%$51.90-1.5%+49.6%$3.13B$312.97M-14.64990Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageACADACADIA Pharmaceuticals3.4895 of 5 stars$18.51-0.8%$25.25+36.4%-26.4%$3.08B$726.44M23.72510Gap DownXENEXenon Pharmaceuticals2.6186 of 5 stars$39.58-1.0%$56.00+41.5%-16.8%$3.02B$9.43M-14.04210Options VolumeNews Coverage Related Companies and Tools Related Companies Rhythm Pharmaceuticals Alternatives Crinetics Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Immunovant Alternatives Viking Therapeutics Alternatives Arcellx Alternatives Denali Therapeutics Alternatives Twist Bioscience Alternatives ACADIA Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REPL) was last updated on 2/8/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredBig Tech’s $17 Trillion Reckoning DayThe world's biggest tech companies are silently sounding the alarm. While everyday investors keep piling in...InvestorPlace | SponsoredThe Secret Winner in Trump’s AI RevolutionTrump just announced a $500 billion plan to revolutionize artificial intelligence. He's calling it The Star...Behind the Markets | SponsoredCould 1 of these 5 “America First” stocks 26x from here?Tim Bohen says these 5 tiny “America First” stocks are next up in 2025. They’re trading for less than $2 ri...Timothy Sykes | SponsoredElon Musk’s secret rendezvous with Jensen HuangElon Musk is the world's richest person, and it's not even close. Now he's got the ear of President Trump, ...Weiss Ratings | SponsoredSteve Bannon Sounds Alarm On Elon Musk’s ‘Indefensible Betrayal’Now, if Elon Musk was truly an America First champion… His cronies wouldn't be bragging to the New York Tim...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.